Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03204266 · ClinicalTrials.gov registry record · Early Phase 1
Oral Supplementation to Enhance Recovery Pilot Study
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
NCT03204266: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03204266 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03204266, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the supplements Pro-Stat (which has l-arginine and also contains protein) and omega-3 fatty acids will be well tolerated in patients who have radical cystectomy for bladder cancer. Researchers also want to learn how these medications affect inflammation and recovery for these surgical patients. This is an investigational study. Pro-Stat is not FDA-approved to treat any specific condition or disease. Omega-3 fatty acids are FDA-approved to treat high triglyceride levels. Their use to treat inflammation and help improve recovery after bladder cancer surgery is investigational. The study doctor can explain how the supplements are designed to work. Up to 46 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- DIETARY_SUPPLEMENT Omega-3 Fatty Acids
- DRUG Arginine recovery supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2022-05-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03204266
The ClinicalTrials.gov registry entry for NCT03204266 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omega-3 Fatty Acids is the first listed.
NCT03204266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03204266 about?
NCT03204266 is a clinical study titled "Oral Supplementation to Enhance Recovery Pilot Study". The goal of this clinical research study is to learn the supplements Pro-Stat (which has l-arginine and also contains protein) and omega-3 fatty acids will be well tolerated in patients who have radical cystectomy for bladder cancer. Researchers also want to learn how these medications affect inflam...
What is the current status of trial NCT03204266?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2017-08-16. Estimated completion is 2022-05-25.
What interventions are being tested in trial NCT03204266?
The interventions under investigation include: Omega-3 Fatty Acids (DIETARY_SUPPLEMENT), Arginine recovery supplement (DRUG).
Who is sponsoring clinical trial NCT03204266?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.